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OBJECTIVE — Todeterminewhetherdialysistreatmentisanindependentriskfactorforfoot
ulceration in patients with diabetes and renal impairment.
RESEARCH DESIGN AND METHODS — We performed a cross-sectional study of
consecutive patients with diabetes and stage 4 or 5 chronic kidney disease (CKD) attending
clinicsinManchester(U.K.).Patientswereclassiﬁedaseitherreceivingdialysistherapy(dialysis)
ornot(nodialysis).Footassessmentincludeddiabeticperipheralneuropathy(DPN),peripheral
arterial disease (PAD), prior foot ulceration and amputation, and foot self-care. Risk factors for
prevalent foot ulceration were assessed by logistic regression.
RESULTS — We studied 326 patients with diabetes and CKD (mean age 64 years; 61% male;
78% type 2 diabetes; 11% prevalent foot ulceration). Compared with no dialysis patients,
dialysis patients had a higher prevalence of DPN (79 vs. 65%), PAD (64 vs. 43%), prior ampu-
tations(15vs.6.4%),priorfootulceration(32vs.20%),andprevalentfootulceration(21vs.5%,
all P  0.05). In univariate analyses, foot ulceration was related to wearing bespoke footwear
(odds ratio 5.6 [95% CI 2.5–13]) dialysis treatment (5.1 [2.3–11]), prior foot ulceration (4.8
[2.3–9.8],PAD(2.8[1.3–6.0],andyearsofdiabetes(1.0[1.0–1.1],allP0.01).Inmultivariate
logistic regression, only dialysis treatment (4.2 [1.7–10], P  0.002) and prior foot ulceration
(3.1 [1.3–7.1], P  0.008) were associated with prevalent foot ulceration.
CONCLUSIONS — Dialysis treatment was independently associated with foot ulceration.
Guidelines should highlight dialysis as an important risk factor for foot ulceration requiring
intensive foot care.
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T
helifetimeriskofanindividualwith
diabetes developing foot ulceration
has been estimated to be 25% (1).
Foot ulceration is a serious problem for
peoplewithdiabetes,whichalsoresultsin
huge economic costs (2).
Causal pathways to foot ulceration
are multifactorial and involve combina-
tionsofphysiologicalandmechanicalfac-
tors, self-care, and treatment factors.
Diabetic nephropathy has been identiﬁed
to be an important risk factor for foot ul-
ceration and amputation (3,4). Retro-
spective studies in patients with diabetes
have shown that incident foot ulceration
increases with progressive renal impair-
ment (5), and one study reported a close
temporal relation among the onset of di-
alysis, foot ulceration, and amputations
(6).
Studies reporting an association be-
tween renal failure and foot ulceration
havefailedtoseparatedialysis-treatedpa-
tients from those not receiving dialysis
(5,7). We therefore aimed to determine
whether dialysis treatment is an indepen-
dent risk factor for foot ulceration among
diabetic patients with stage 4 or 5 chronic
kidney disease (CKD). We hypothesized
that dialysis treatment would be associ-
ated with a higher prevalence of foot ul-
ceration after adjustment for potential
confounders.
RESEARCH DESIGN AND
METHODS— Study participants
were consecutive patients with diabetes
and stage 4 or 5 CKD attending either
Manchester Diabetes Centre, the renal
anddialysisunitsofManchesterRoyalIn-
ﬁrmary, or one of the satellite dialysis
units in the area between October 2006
and March 2008. Stage 4 or 5 CKD was
deﬁned as average Modiﬁcation of Diet in
Renal Disease (MDRD) estimated glomer-
ular ﬁltration rate (eGFR) 30 ml/min
over the preceding year (8). These pa-
tients were classiﬁed according to dialysis
status into the following two groups. 1)
The no dialysis group included patients
with MDRD eGFR values 30 ml/min
who were not receiving dialysis treat-
ment. This group included some patients
who were considered to be unsuitable for
dialysis treatment for medical reasons or
because of patient preference. 2) The di-
alysis group included patients with end-
stage renal disease (ESRD) currently
receiving either hemodialysis or perito-
neal dialysis treatment.
At clinic visits, using a routine data
entry form, the study clinician collected
data both from patients and from the
medical notes. Data included the follow-
ingvariables:diabetestype,duration,and
treatment, previous foot ulcers and am-
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history of retinopathy, and the onset and
currentmodalityofdialysis(hemodialysis
or peritoneal dialysis). Foot self-care was
assessed by patient self-report with four
items using the following format: Do you:
Currently use bespoke footwear or insoles?
Attend regular podiatry? Walk barefoot at
home? Inspect your feet daily? Responses to
these questions were recorded as yes/no.
Diabetic peripheral neuropathy
(DPN) was assessed by measuring the vi-
bration perception threshold (VPT) with
a neurothesiometer (Horwell Scientiﬁc,
Wilford, Nottingham, U.K.) over the dis-
tal hallux as described previously (9) and
clinical examination using the modiﬁed
neuropathy disability score (NDS). DPN
was deﬁned as VPT 25 V and/or a mod-
iﬁedNDS3(10).Peripheralarterialdis-
ease (PAD) was assessed through
palpation of the posterior tibial and dor-
salis pedis pulses bilaterally, determina-
tion of the ankle brachial pressure index
(ABPI) using a Doppler ultrasound probe
in both legs. In addition, records were re-
viewed for documented evidence of an-
giographically conﬁrmed PAD and/or
revascularization. PAD was deﬁned as at
least one of the following: ABPI 0.9
(11),ahistoryofaperipheralarteryrevas-
cularization procedure or angiography
conﬁrming PAD, noncompressible arter-
ies (deﬁned as ABPI 1.4), abnormal
waveforms (monophasic or biphasic)
with ABPIs of 0.9–1.4 (12), or absence of
two or more pedal pulses on palpation
(13). Major amputations were deﬁned as
amputations proximal to the ankle joint,
and minor amputations were deﬁned as
those through or distal to the ankle joint.
Foot deformity was ascertained by the ex-
aminingphysicianandwasdeﬁnedasany
one of the following: hallux valgus defor-
mity, claw/hammer toes, prominent
metatarsal heads, dislocated metatarso-
phalangeal joints, pes cavus (high plantar
arch),orpesplanus(ﬂatfoot).Allofthese
assessments are routinely performed in
our combined diabetes-renal clinics.
The International Working Group on
the Diabetic Foot (IWGDF) risk classiﬁ-
cation was used to assign patients into
four levels of increasing risk of foot prob-
lems (13): 1) risk 0, no recognizable risk
factor; 2) risk 1, neuropathy and no other
riskfactors;3)risk2,PADwithorwithout
neuropathy; and 4) risk 3, current foot
ulcer, a history of foot ulcer, or prior am-
putation.Patientsinriskcategory0where
considered to be at “low risk” for foot ul-
ceration, whereas those in risk categories
1–3 were considered to be at “high risk.”
Thisstudywasperformedasanauditthat
required no formal ethics permission. As
mentioned above, data collected are part
of routine care provided to patients in the
study centers. However, all subjects gave
informedverbalconsentbeforeinclusion.
Pearson
2andFisherexacttestswere
usedtocomparecategoricaldatabetween
study groups. The 95% CIs for propor-
tions and percentages were estimated us-
ing the modiﬁed Wald formula. The
Student t test was used to compare con-
tinuous data. Risk factors for foot ulcer-
ation were assessed by univariate logistic
regression. Risk factors signiﬁcantly asso-
ciated with prevalent foot ulceration in
univariate analysis (P  0.1) were then
included in the multivariable logistic re-
gression analysis. Peripheral neuropathy
was “forced” in this model because of its
known association with foot ulceration.
Risk estimates were presented as odds ra-
tios (ORs) with 95% CIs, and P  0.05
was considered statistically signiﬁcant.
All analyses were performed using SPSS
(version 16.0; SPSS, Chicago, IL).
RESULTS— We assessed 326 patients
(139dialysis-treatedand187nodialysis).
Within the dialysis group, 85 patients
(61%) were treated with hemodialysis,
andtheremainderweretreatedbyperito-
neal dialysis. The median (interquartile
range) time between clinical assessment
and the start of dialysis was 16 (6–30)
months.Clinicalcharacteristicsweresim-
ilar in dialysis-treated and no dialysis pa-
tients except that dialysis-treated patients
were 8 years younger and were more
likely to have type 1diabetes and a lower
serum albumin concentration (Table 1).
The overall prevalence of foot ulcers
was 11% (36 patients). Ten percent of all
patients had a prior lower limb amputa-
tion. Eight patients in the dialysis group
were bilateral amputees; only those 131
patients with at least one lower limb were
included in the prevalence analyses.
There were no patients with bilateral am-
putations in the no dialysis group.
Thirteen of the 20 amputees (65%) in
the dialysis group had undergone major
amputation. Although this result was
higher, it was not signiﬁcantly different
from the 7 major amputations of 12 am-
putees (58%) in the no dialysis group
(P  0.50).
Of the 27 patients in the dialysis
group who had at least one current ulcer,
the ulcers were located on metatarsal
heads (n  2), plantar midfoot (n  2),
heel(n3),distaltoes(n18),multiple
sites (n  1), and unspeciﬁed (i.e., not
recorded) location (n  1). Among the 9
patients with ulcers in the no dialysis
group, the sites of ulceration were toes
(n  2), metatarsal head (n  1), midfoot
(n  1), dorsal foot (n  1), heel (n  2),
and multiple sites (n  2).
Dialysis treatment was associated
with a ﬁvefold higher prevalence of prev-
alentfootulceration,atwofoldhigherrisk
ofprioramputation,priorfootulceration,
DPN, and PAD, and a lower prevalence of
foot deformity compared with no dialysis
treatment(Table2).BasedontheIWGDF
classiﬁcation, dialysis-treated patients
were3timesmorelikelytobeclassiﬁed
ashavingahighriskofdiabeticfootulcers
compared with no dialysis patients (P 
0.015). Preventative foot care behavior
was better in the predialysis than in the
dialysis group except for the use of be-
spoke footwear.
When the dialysis and no dialysis
groupswerecombined,univariatelogistic
regression showed that prevalent foot ul-
ceration was signiﬁcantly related to wear-
ing bespoke footwear, dialysis therapy,
Table 1—Clinical characteristics of no dialysis and dialysis-treated patients
Characteristic No dialysis Dialysis P value
n 139 187
Ethnicity: African/Southeast Asian/white (%) 11/20/69 10/24/66 0.70
Male sex (%) 56 64 0.09
Age (years) 67  12 59  14 0.0001
Diabetes type: 1:2 and others (%) 17:83 25:75 0.041
Known diabetes duration (years) 19  11 20  11 0.51
A1C (% units) 7.8  1.6 8.0  1.7 0.29
Serum albumin (g/l) 40  53 6  6 0.0001
Hemoglobin (g/dl) 11.8  1.5 11.5  1.7 0.07
Retinopathy (%) 69 70 0.43
Data are n, %, or means  SD.
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tendance at a podiatry clinic (Table 3). In
multivariable analysis prevalent foot ul-
ceration was signiﬁcantly and indepen-
dently related to dialysis therapy and
history of foot ulceration (Table 3).
In the combined dialysis and no dial-
ysis patient groups, prevalent and prior
foot ulceration and prior amputation did
not vary by ethnic group using ANOVA
and when whites were compared with
otherindividualethnicgroups.Therewas
a suggestion that whites were more likely
than nonwhites to have a prevalent foot
ulcer (OR 2.5 [95% CI 1.1–6.0] P 
0.051).
The proportion of patients classiﬁed
asbeingathighrisk,basedontheIWGDF
risk categories was equally high in all eth-
nic groups (NS). All Africans (14 pa-
tients), all Asians (33 patients) and 83 of
92 white patients in the dialysis group
were classiﬁed as being at high risk,
whereassimilarly,18of20Africans,32of
37 Asians, and 108 of 130 white patients
in the no-dialysis group were classiﬁed as
being at high risk for foot ulceration. The
rest of the patients were classiﬁed as low
risk.
Withinthewhitesubgroup,prevalent
foot ulceration was more common in di-
alysis-treatedpatientsthannodialysispa-
tients (OR 6.0 [95% CI 2.4–14.7], P 
0.0001) and those who were dialysis-
treated were also more likely to have had
an amputation (2.4 [1.0–5.9], P  0.04).
Thenumbersofpatientswithafootulcer-
ation or amputation in the African or
Asian ethnic groups were too small to
be analyzed by dialysis/no dialysis sub-
group.
Among the no dialysis patients, DPN,
PAD, past and current foot ulcers, and
prior amputation did not vary by ethnic-
ity (ANOVA). When whites were used as
the referent group, Asians were less likely
Table2—ORs(95%CI)forprevalentfootcomplicationsandassociatedriskfactorscomparing
dialysis-treated patients and no dialysis patients
No dialysis* Dialysis* OR (95% CI) P value
n 187 139
Lower limb complications
Prevalent foot ulcer (%) 4.8 21 5.1 (2.3–11) 0.0001
Prior amputation (%) 6.4 15 2.6 (1.2–5.6) 0.008
PAD (%) 43 64 2.4 (1.5–3.8) 0.0001
Neuropathy (%) 65 79 2.0 (1.2–3.3) 0.006
Prior foot ulcer (%) 20 32 1.9 (1.1–3.1) 0.011
Deformity (%) 33 22 0.6 (0.4–1.0) 0.019
IWGDF risk categories (%)
Low-risk category 0 16 7
High-risk category 1 12 17
High-risk category 2 43 39
High-risk category 3 29 37
Low-risk vs. high-risk category 16 vs. 85 7 vs. 94 2.7 (1.2–5.8) 0.015
Patient care
Use of bespoke footwear (%) 8 16 2.6 (1.2–4.3) 0.026
Walking barefoot at home (%) 28 43 2.0 (1.2–3.1) 0.004
Routine podiatry clinic attendance (%) 70 44 0.3 (0.2–0.5) 0.0001
Daily inspection of feet (%) 70 29 0.2 (0.1–0.3) 0.0001
Data are proportions as % unless otherwise indicated. *Values of n for individual factors may differ slightly
because of missing data. Maximum missing data were for PAD involving 6 patients overall (1.8%). The
referent group for calculation of ORs was the no dialysis patient group.
Table 3—Univariate and multivariable-adjusted ORs (95% CI) for risk factors associated with prevalent foot ulceration in patients with
diabetes and renal impairment
Risk factor
Prevalent foot ulcer Univariate analysis
Multivariable-adjusted
analysis
Yes No OR (95% CI) P value OR (95% CI) P value
n 36 281
Wearing bespoke footwear 33 8.3 5.6 (2.5–13) 0.0001 2.2 (0.8–6.0) 0.129
Dialysis treatment 75 37 5.1 (2.3–11) 0.0001 4.2 (1.7–10) 0.002
History of foot ulcer 56 21 4.8 (2.3–9.8) 0.0001 3.1 (1.3–7.1) 0.008
PAD 72 48 2.8 (1.3–6.0) 0.009 1.6 (0.7–3.9) 0.257
White ethnicity 83 67 2.5 (1.0–6.1) 0.051 1.8 (0.7–4.9) 0.229
Retinopathy 81 69 1.9 (0.8–4.5) 0.144
Neuropathy 81 71 1.5 (0.7–4.0) 0.245 0.7 (0.3–2.0) 0.542
Male sex 64 59 1.2 (0.6–2.6) 0.553
Walking barefoot at home 36 34 1.1 (0.5–2.2) 0.840
Known diabetes duration (years)* 24  13 19  11 1.0 (1.0–1.1) 0.009 1.0 (0.9–1.1) 0.121
Duration of dialysis (months)† 24 (28) 15 (22) 1.0 (0.9–1.1) 0.345
Age (years)* 61  12 64  14 1.0 (0.9–1.1) 0.120
Deformity 28 30 0.9 (0.4–2.0) 0.827
A1C (%) 7.7  1.3 7.9  1.7 0.9 (0.7–1.1) 0.385
Routine podiatry clinic attendance 44 62 0.5 (0.3–1.0) 0.055 0.9 (0.4–2.0) 0.707
Dataareproportionsas%,meansSD,ormedian(IQR)unlessotherwiseindicated.VariableswithP0.1inunivariateanalysiswereincludedinthemultivariable
analysis. In univariate analysis, duration of dialysis excluded no dialysis patients. The referent group for calculation of the OR was the no foot ulcer group. *OR
calculated per year of exposure variable. †OR calculated per month of exposure variable.
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P  0.03) and Africans were less likely to
haveDPN(0.3[0.1–0.8],P0.011).We
have recently reported the inﬂuence of
ethnicity on diabetic foot ulcers in dialy-
sis-treated patients.
The proportion of patients with prev-
alent foot ulceration in the group receiv-
ing hemodialysis was similar to that of
those receiving peritoneal dialysis (22
[95% CI 15–32] vs. 17 [9–31]%, P 
0.33). The prevalence of prior amputa-
tion was higher in patients receiving he-
modialysis than in those receiving
peritoneal dialysis (21 [13–30] vs. 6
[2–17]%, OR 3.9 [1.1–14], P  0.02).
CONCLUSIONS — We have shown
that in patients with diabetes and stage 4
or 5 CKD, prevalent foot ulceration was
ﬁvefold higher in dialysis-treated patients
than in predialysis patients. We also re-
port that the prevalence of other lower
limb complications (amputation, PAD,
priorulcer,andneuropathy)was2-fold
higher in patients receiving dialysis. The
strong association between prevalent foot
ulceration and dialysis therapy remained
signiﬁcant after adjustment for potential
confounders (neuropathy, PAD, ethnic-
ity, known duration of diabetes, and use
of footwear).
We performed a detailed, systematic
foot assessment on a relatively large co-
hort of well-characterized patients with
diabetes and CKD. Our ascertainment of
risk factors for foot ulceration and our
prevalence estimates for lower limb com-
plications are therefore likely to be accu-
rate. We made foot ulceration our
primary outcome because it can be ascer-
tained cross-sectionally, it is potentially
preventable,anditusuallyprecedesmore
serious foot complications such as severe
infection, gangrene, or amputation. We
carefully chose our no dialysis compara-
tor group to include patients with stage 4
or5CKDwhowerenotdialysistreatedso
that any differences compared with the
dialysis group would be more likely to be
due to the dialysis treatment itself. We
found that dialysis-treated patients had
more peripheral neuropathy, PAD, and
previous foot ulceration and amputations
than no dialysis patients. In our multiva-
riablemodelwethereforeadjustedforthe
markers of advanced disease because
these might have confounded the rela-
tionship between dialysis therapy and
foot ulceration.
This study has several limitations.
The cross-sectional design limits infer-
ence about causal relationships between
dialysis and prevalent foot ulceration.
Our cohort was largely white, and, there-
fore, our conclusion may not apply to
other ethnic groups. However, the inclu-
sion of ethnicity in our ﬁnal multivariable
model did not attenuate the relationship
between dialysis and foot ulcers. Our
study sample was insufﬁcient to reliably
compare the site of foot ulceration in di-
alysis and no dialysis groups. We did not
systematically assess the site and severity
of peripheral edema and the severity of
PAD, which are potential confounders of
the relationship between dialysis therapy
and ulceration.
McGrath and Curran (14) provided
one of the ﬁrst reports that dialysis is a
risk factor for foot complications in pa-
tients with diabetes and CKD. This was a
small retrospective study in New Zealand
of 47 patients with prior amputation, 32
(68% [32/47]) of whom were Maoris. In
14 patients who were dialysis-treated, the
median time between starting dialysis to
having an amputation was 7 months
(range 2 weeks–40 months). Subse-
quently, Morbach et al. (15) examined a
predominantly white population of 400
patients with diabetic foot ulcers, a small
proportion of whom (14 [4%]) were dial-
ysis-treated. Although the number of
events was small, the amputation rates
were higher in the dialysis-treated pa-
tients (57%) than in others with (25%) or
without (5%) CKD. In contrast with the
studies of Morbach et al. and McGrath
andCurran,ourstudyfocusedondialysis
as a risk factor for foot ulceration rather
than for amputation.
Game et al. (6) performed a retro-
spective case series analysis of 90 patients
with diabetes who started dialysis and
showed that the cumulative incidence of
foot ulceration and amputation increased
before the initiation of dialysis and then
was highest during the next 2 years. Be-
cause the increase in foot complications
occurred just before dialysis, it remained
unclear whether the main driver of foot
complications in the study cohort was
ESRD or dialysis treatment itself.
Hilletal.(16)alsoperformedacross-
sectional assessment of patients with dia-
betes (n  60 with ESRD and n  72
without ESRD) and found that ESRD was
associated with a fourfold higher risk of
diabetic foot complications, which were
deﬁned as current infection, ulcer, gan-
grene, or amputation. However, this
study did not speciﬁcally relate risk to di-
alysis therapy. The study also had a com-
posite outcome, and the level of renal
function in those without ESRD was not
deﬁned.
A recent cross-sectional retrospective
study by Wolf et al. (7) showed that the
risk and severity of foot ulceration were
relatedtotheseverityofrenalimpairment
in patients with diabetes. However, the
study included only 61 patients with
stage 5 CKD and in this group did not
differentiatedialysis-treatedpatientsfrom
others and made limited adjustment for
confounders such as neuropathy and
PAD. Our study, therefore, adds to the
existingevidencethatdialysisisariskfac-
tor for foot ulceration, in addition to the
impact of poor renal function.
Itseemsverylikelythatseveralfactors
explain the link between dialysis therapy
and foot ulceration, only some of which
we were able to address in our study.
These factors include physical and psy-
chological health, mobility, manual
dexterity, visual acuity, nutrition, hy-
poalbuminemia, adequacy of dialysis,
PAD, tissue oxygenation, neuropathy,
anemia,legedema,infection,andleg/foot
support during dialysis.
The detailed etiopathogenesis of foot
ulcers in relation to dialysis has been re-
viewed (17). Foot ulceration could be
caused by lying on a dialysis couch for
several hours three times a week, espe-
cially on insensate heels or with the toes
impinging on the end of the bed. Hemo-
dynamic changes and large ﬂuid shifts as-
sociated with dialysis could predispose to
posturaldizziness,falls,andtraumatothe
foot. During hemodialysis there is a re-
duction in skin microcirculation and tis-
sue oxygenation that may contribute to
the development of ulceration in patients
with diabetes (18). Further studies are
needed to assess the role of dialysis mo-
dality, including an evaluation of the ad-
equacy of dialysis.
We found that dialysis-treated pa-
tients were less likely to inspect their feet
regularly and to attend podiatry clinics.
Moreover, they were more likely to en-
gage in potentially foot-damaging behav-
iors such as barefoot walking. These are
believed to be potentially modiﬁable foot
self-care actions (19), and further re-
search is needed to establish whether im-
provement in these behaviors results in
reduction of foot ulceration in dialysis-
treated patients.
The likelihood of wearing bespoke
shoes was higher in the dialysis group
comparedwiththenodialysisgroup.This
couldbeexplainedbythefactthatalarger
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had prevalent (active) foot ulcers at the
time of this cross-sectional investigation.
It is also conceivable that patients might
follow some behavioral recommenda-
tions more readily than the others. For
example, wearing prescribed footwear
may require less of a deliberate effort on
the part of an individual than attending
regular podiatry clinics or checking the
insideoftheshoes,especiallybecauseitis
known that patients with ESRD are likely
to be depressed (20) and thus be in the
state of behavioral disengagement.
There are some data suggesting that
PADisanindependentlinkbetweenCKD
and foot disease (21,22). We found that
PAD was not associated with prevalent
foot ulceration after adjustment for other
factors including dialysis therapy. This
ﬁnding contrasts with our recently pub-
lished data in dialysis-treated patients in
whom we found an independent associa-
tion between PAD and prevalent foot ul-
ceration (23). The discrepant results may
be explained by two factors: 1) inclusion
of U.K.- and U.S.-based dialysis-treated
patients in our previous study; and 2)i n
thecurrentstudy,theinﬂuenceofdialysis
therapy attenuating the impact of PAD on
prevalent foot ulceration when the inter-
related PAD and dialysis variables were
included in the same model. Further-
more,anotherlargestudyinpatientswith
diabetesshowedthatPADdidnotexplain
the link between CKD and foot complica-
tions, but this study did not assess the
inﬂuence of dialysis (5).
It is noteworthy that all the ethnic
groups we studied displayed a high prev-
alence of the high-risk foot, based on the
IWGDF risk categorization. In addition,
the strong association between dialysis
and foot ulcers was not signiﬁcantly af-
fected by ethnicity in our multivariable
analysis. These ﬁndings lend support to
data from previous studies (5,6,14–16)
andourownwork(23)suggestingthatall
dialysis-treated diabetic patients are at
high risk for foot complications.
Our ﬁndings have important clinical
implicationsastheyalerthealthcareprac-
titioners that dialysis is an independent
riskfactorforfootulceration,thusrequir-
ing extra vigilance and foot care. Current
diabetes guidelines and recommenda-
tions fail to recognize the strength of the
link between dialysis treatment and foot
ulceration (11,13). Our ﬁndings suggest
that in terms of foot ulcer risk, dialysis
treatment should be ranked equivalent to
a history of previous foot ulceration (i.e.,
risk category 3, IWGDF classiﬁcation).
This is analogous to diabetes being
ranked equivalent to a history of prior
myocardial infarction with respect to cor-
onary heart disease risk (24).
Wesuggestthatpatientsduetostart
dialysis and those receiving dialysis
shouldhaveintensiveeducationinclud-
ing the initiation of measures to prevent
foot ulceration. The efﬁcacy and cost ef-
fectiveness of preventive foot care in
these patients needs to be evaluated in
carefully designed intervention studies.
While results from such studies are
awaited, current foot care guidelines
should emphasize the importance of di-
alysis therapy as a risk factor for foot
ulceration.
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